enGene Therapeutics Inc.
ENGNNasdaqCIK 1980845HealthcareFiscal year ends Oct 31
Reports and events: 71 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0807:36 ET | 10-Q | Quarterly reportPeriod 2026-07-31 | 0001193125-26-384383 |
| 2026-09-0807:33 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-384380 |
| 2026-08-1116:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-344559 |
| 2026-07-1716:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-307795 |
| 2026-07-1608:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-305418 |
| 2026-06-1816:06 ET | 8-K/A | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors | 0001193125-26-275815 |
| 2026-06-1509:16 ET | 10-Q | Quarterly reportPeriod 2026-04-30 | 0001193125-26-270386 |
| 2026-06-1509:14 ET | 8-K | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270384 |
| 2026-06-1016:09 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-265830 |
| 2026-05-0816:06 ET | DEF 14A | Proxy statementPeriod 2026-06-09 | 0001140361-26-020024 |
| 2026-05-0707:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-210316 |
| 2026-04-0916:02 ET | 8-K | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-149597 |
| 2026-03-0907:15 ET | 8-K | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-097546 |
| 2026-03-0907:09 ET | 10-Q | Quarterly reportPeriod 2026-01-31 | 0001193125-26-097541 |
| 2026-03-0907:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-097534 |
| 2026-02-1916:15 ET | 10-K/A | Annual report, amendedPeriod 2025-10-31 | 0001193125-26-059409 |
| 2026-01-2116:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-017945 |
| 2026-01-2107:38 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-017226 |
| 2025-12-2216:11 ET | 10-K | Annual reportPeriod 2025-10-31 | 0001193125-25-328743 |
| 2025-12-2216:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-328706 |
| 2025-11-1416:39 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-283182 |
| 2025-11-1206:16 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-275722 |
| 2025-10-0216:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-228351 |
| 2025-10-0216:13 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001193125-25-228331 |
| 2025-09-3007:36 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-224053 |
| 2025-09-1116:11 ET | 10-Q | Quarterly reportPeriod 2025-07-31 | 0000950170-25-114224 |
| 2025-09-1116:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-114220 |
| 2025-09-0307:56 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-112674 |
| 2025-07-0808:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000929638-25-002520 |
| 2025-06-1208:08 ET | 10-Q | Quarterly reportPeriod 2025-04-30 | 0000950170-25-085143 |
| 2025-06-1208:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-085138 |
| 2025-06-1017:26 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000929638-25-002215 |
| 2025-06-0907:29 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000950170-25-083444 |
| 2025-06-0408:35 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000929638-25-002133 |
| 2025-05-0916:05 ET | DEF 14A | Proxy statementPeriod 2025-06-10 | 0001140361-25-018155 |
| 2025-03-1016:10 ET | 10-Q | Quarterly reportPeriod 2025-01-31 | 0000950170-25-036281 |
| 2025-03-1016:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-036264 |
| 2025-02-2016:38 ET | 10-K/A | Annual report, amendedPeriod 2024-10-31 | 0000950170-25-024221 |
| 2024-12-2006:59 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0000950170-24-138767 |
| 2024-12-1916:22 ET | 10-K | Annual reportPeriod 2024-10-31 | 0000950170-24-138472 |
| 2024-12-1916:09 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000950170-24-138446 |
| 2024-11-0116:04 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-249815 |
| 2024-10-2508:10 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-243481 |
| 2024-10-2108:47 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-115767 |
| 2024-10-1816:15 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-239641 |
| 2024-09-2606:33 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-109463 |
| 2024-09-1016:38 ET | 10-Q | Quarterly reportPeriod 2024-07-31 | 0000950170-24-105180 |
| 2024-09-1016:34 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-105175 |
| 2024-09-0506:46 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-103727 |
| 2024-07-2406:50 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-183292 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:16 ET. Listed shows no prices and gives no investment advice.